| Revenue guidance | 20.0% → 5.0% Cut by 15.0 percentage points |
|---|
| Revenue growth | -42% YoY; -57% QoQ. |
|---|---|
| Margins | EBITDA margin contracted 624 bps YoY to 23.3%. |
| Order book | CRAMS pipeline on track; projects contribute from H2FY27. |
| Demand visibility | Subdued European demand persisting into Q2FY27. |
| Management confidence | Confident in H2FY27 recovery via direct sales and CRAMS. |
Growth
Revenue from operations fell 42% YoY to ₹14.36 Cr; PAT dropped 68% YoY to ₹1.12 Cr.
Outlook
Moderated FY27 non-linear growth guidance. Block 7 commissioning H1FY27; ₹15 Cr FY26 capex for R&D and expansion.
Risks
Subdued European demand; raw material volatility; termination of key EU marketing agreement leading to temporary volume loss.
Investor Presentation filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹672.35
- Market cap
- ₹863.1 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 55.9×Sector 50.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Q1 FY27 Results: Net Profit ₹1.1 Cr, Down 67.6% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · -67.6% YoY
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Shree Ganesh Remedies Q4 FY26 Results: Net Profit ₹6.3 Cr, Down 4.5% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹33.2 Cr (+36.1% YoY) and net profit of ₹6.3 Cr (-4.5% YoY) for Q4 FY26.
- Key figure
- Net profit ₹6.3 Cr · -4.5% YoY